Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...
Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...
Zacks.com on MSN19h
Merck to End Development of Two Cancer Candidates: Time to Sell?We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...
Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...
One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
For MSD, all eyes are now on KeyVibe-003, which is comparing the drug to Keytruda in previously-untreated PD-L1-positive NSCLC, as well as KeyVibe-006 and KeyVibe-007 looking at first-line use of ...
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback